Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Bone graft & orthobiologics · Pennsylvania | Bone graft & orthobiologics · New York | |
|---|---|---|
| Surgeons, 2024 | 25 | 21 |
| Medicare fee-for-service cases | 1,024 | 796 |
| Growth since 2019 (Medicare FFS) | −12%/yr | −5%/yr |
| Forecast cases (Medicare FFS) | 1,010 in 2030 | 810 in 2030 |
| Forecast growth | −0.2%/yr to 2030 | +0.2%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.7 | 0.4 |
| Medicare Advantage share | 58% | 57% |
| Out of hospital | 0% (+0 pts since 2019) | 1% (+1 pts since 2019) |
| Cases per surgeon | 41 | 38 |
| Top 10 surgeons' share | 63% | 65% |
| Surgeons growing | 2 | 1 |
| New since the base year | 1 | 1 |
| Likely to stop billing it | 5 by 2026 | 6 by 2026 |
| Forecast miss, 1 year (procedure) | 12% | 12% |
| Company payments per surgeon | $12K | $15K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.